Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

s of this study suggested that maximum benefit accrued to patients whose LDH did not exceed 80% of the upper limit of normal for LDH. Efficacy results in this group of 274 patients (who are the focus of the new AGENDA trial) are displayed in the table below. The hazard ratios indicate that the addition of Genasense to DTIC was associated with a 42% reduction in the risk of disease progression and a 36% reduction in risk of death.

Endpoint Genasense/DTIC DTIC Hazard P

Ratio

Overall response 20.8% 7.2% 0.002

Durable response 10.7% 2.4% 0.007

Progression-free

survival, median 3.6 mos. 1.6 mos. 0.58 <0.0001

Overall survival,

median 12.3 mos. 9.9 mos. 0.64 0.0009

About Melanoma

Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the US. In 2004, the American Cancer Society estimates more than 55,000 cases of malignant melanoma will have been diagnosed. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation: http://www.melanoma.org. The EADO is an international cooperative group dedicated to promote, coordinate and improve clinical and laboratory research activities in skin cancer. Further information about the EADO can be viewed at: http://www.eado.org/.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two ma
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 A hernia is condition ... protrudes through the wall of a weak muscle area. Obesity, ... are some of the causes of hernias. There are several ... incisional. An inguinal hernia is when part of the abdominal ... found in the area of the umbilicus. A hiatal hernia ...
(Date:11/26/2014)... 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical company ... infectious diseases, announced today the addition of ... opinion leader in the areas of pneumonia and ... Founder and Chief Executive Officer, Vu ... extensive experience investigating bacterial toxins and key mechanisms ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... NovaRx Corporation announced today the appointment of Norrie ... Chief Operating Officer. Dr. Russell brings to the ... and a long history of success driving innovation in ... leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) ... milestones,achieved in 2008 and preview objectives for 2009 during ... New York City today. , David Smoller, ... discuss the progress and expected potential of the,two companies, ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6
(Date:11/27/2014)... Los Angeles, CA (PRWEB) November 27, 2014 ... are thrilled to be part of Omadox, a feature ... Film Festival, including an award for best ensemble cast. It ... Festival. This is a great start to a successful cinematic ... experimental/sci-fi, black and white movies. If you enjoy experimental mystery, ...
(Date:11/27/2014)... Acapulco, Guerrero (PRWEB) November 27, 2014 ... the time individuals allot to sleep has lessened, ... televisions and laptops, the quality of sleep has ... workers falls asleep on the job (Reference: ... American worker’s productivity index by an incalculable amount, ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows that ... and she wants to lessen its impact. "After showering ... that there needed to be a way to maintain ... use and producible in design variations, the End Scentuous ... throughout the day. It avoids bad odors, as well ...
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... Will Feature Nearly 100 Exhibits, Forums on Health Care ... Health Screenings and Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ... largest advocacy organization for people age 50+, today announced ... event to San Antonio on May 15-16. ...
... But it,s unlikely these factors cause the neurological condition, experts ... older mothers and children who have breech deliveries are almost ... researchers report. , The findings confirm those of other studies ... genetic base, researchers say. , "A child with breech ...
... surgeons can agree! There is often disagreement between ... the proper therapy for coronary artery disease (CAD)and ... edition of Deutsches rzteblatt International , an ... cardiac surgeons provides answers to the question of ...
... to attend TCT 2009 (Transcatheter Cardiovascular Therapeutics), the ... TCT gathers leading medical researchers and clinicians from ... latest developments in the field of interventional cardiology ... TCT brings state-of-the-art techniques and training to interventional ...
... National Infant Immunization Week is April 25 - May ... To kick off National Infant Immunization Week, ... for all parents to fully immunize their children against ... preventable diseases such as whooping cough, meningitis and measles ...
... IAC for Electronic ClaimsJACKSONVILLE, Fla., April 27 ... today announced that Insurers Administrative Corporation (IAC) has ... compliant electronic claims. As an Availity client, health ... Availity(R) Health Information Network free of charge.(Logo: ...
Cached Medicine News:Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Autism Tied to Older Moms, Breech Birth 2Health News:Autism Tied to Older Moms, Breech Birth 3Health News:Media registration now open for TCT 2009 2Health News:Pennsylvania Secretary of Health Reminds All Parents to 'Be Wise, Immunize Your Children' 2Health News:Insurers Administrative Corporation Joins the Availity Network 2
Wright-Giemsa Stain Solutions...
... For fast, single-solution staining, Hema-Quik ... slides into stain solution for ... to deionized water for five ... second time by dipping quickly ...
... for staining of peripheral blood smears ... stain formulations still in use today. ... of Giemsa stain, although eosinophillic granules ... granules and nuclear chromatin stain a ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
Medicine Products: